Trump signs order to speed review of psychedelics, including controversial drug ibogaine

Lead

President Donald Trump signed an executive order on Saturday directing federal agencies to accelerate the review of psychedelic drugs, including the controversial substance ibogaine, which some military veteran groups have embraced as a potential treatment for post-traumatic stress disorder (PTSD). The order, signed in the Oval Office, instructs the Food and Drug Administration (FDA) to expedite the review process for such drugs and calls for the relaxation of restrictions that have slowed research, according to multiple reports.

Coverage Comparison

Coverage of the announcement was broadly consistent across outlets, though each emphasized different aspects. Al Jazeera and The Guardian focused on the potential benefits for mental health treatment, while the Jerusalem Post highlighted the focus on veterans and ibogaine specifically. The South China Morning Post reported on the FDA's subsequent decision to offer priority review vouchers to three psychedelic drugs, and noted the growing popular support for such substances among Trump's supporters.

Key Claims

• The executive order directs the FDA to expedite review of drugs such as ibogaine, which is currently a Schedule I substance under federal law, as reported by multiple outlets including The Guardian and the Jerusalem Post.
• The order includes $50 million in new federal funding for ibogaine research, according to The Guardian and the Jerusalem Post.
• Researchers have suggested that ibogaine may help treat opioid addiction and other substance abuse problems, as noted by The Guardian and the South China Morning Post.
• Joe Rogan, a prominent podcaster and advocate for psychedelics, was present at the Oval Office signing ceremony and has been credited with influencing the president's interest, per Al Jazeera and The Guardian.
• The FDA has awarded priority review vouchers to three psychedelic drug candidates, including psilocybin for depression and a related compound for PTSD, as reported by the South China Morning Post.

Perspectives

Supporters, including veteran organizations and psychedelic advocates, have long argued that ibogaine holds promise for hard-to-treat conditions such as PTSD and opioid addiction. The order has been described as a significant step toward expanding access to these therapies.

However, some experts caution that the order may have more symbolic than legal impact. Mason Marks, a law professor at Florida State University, told The Guardian that while the concrete provisions may have "some minimal impact," the order's symbolic value is significant. Critics also point to the lack of rigorous clinical trials and the potential risks associated with these substances.

The order has garnered rare bipartisan support, reflecting a shift in attitudes toward psychedelics, particularly among conservative lawmakers and Trump's base.